A phase 2, double-blinded, placebo-controlled trial of toll-like receptor 7/8/9 antagonist, IMO-8400, in dermatomyositis - 10/03/21
Drs Fiorentino and Sarin contributed equally to this article. |
|
Funding sources: Supported by Idera Pharmaceuticals, Inc, Exton, PA. Additional funding was provided by a Stanford University School of Medicine Medical Scholars Grant (to Author Kim). |
|
Disclosure: Dr Chunduru and Author Lees are employees of Idera Pharmaceuticals, Inc. Dr Fiorentino was previously a consultant for Idera Pharmaceuticals. Author Kim, Drs Schiopu, Dankó, Mozaffar, and Goyal, Author Sarazin, and Dr Sarin have no conflicts of interest to declare. |
|
Presented at the 77th Annual Meeting of the Society for Investigative Dermatology (Chicago, IL, May 8-11, 2019; poster presentation), the Rheumatologic Dermatology Annual Meeting (Atlanta, GA, November 9, 2019; oral presentation), and the 2019 American College of Rheumatology Annual Meeting (Atlanta, GA, November 8-13, 2019; oral presentation). |
|
IRB approval status: Reviewed and approved by Stanford University Administrative Panel on Human Subjects in Medical Research (approval no. 4593). |
Vol 84 - N° 4
P. 1160-1162 - avril 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?